Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Polyclinic, a multi-specialty clinic in the Puget Sound area, Washington, US, has introduced a clinical research study - Reveal, which aims to increase HDL (good cholesterol) levels.
Subscribe to our email newsletter
The clinic has opned a new department to conduct the study.
Reveal will test the efficacy of the new drug Anacetrapib to boost HDL levels in patients 50 years or older who have a history of heart attack, coronary artery disease or type I or II diabetes.
The research is sponsored by Oxford University and will include 30,000 individuals worldwide with 180 sites in the US.
According to the company, currently niacin therapy is available with an effect on HDL, which can increase the levels by 20% to 30% but is likely to cause side effects.
Polyclinic cardiologist and principal investigator for the Reveal study Kier Huehnergarth said through the research, The Polyclinic hopes to provide patients with even more protection against a future heart attack.